Please assess the completion status of the following clinical trial:

Trial Title: Sleep Position May Reduce Acid Reflux Symptoms at Night

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients between the ages of 18 and 65;~* Between 5'4 and 6'2~* Body Mass Index\<32~* Willing and able to provide written informed consent;~* Understands the clinical study requirements and is able to comply with the follow-up schedule set forth in the protocol;~* Clinically diagnosed with gastroesophageal reflux disease with extra-esophageal symptoms (i.e. chronic cough, choking, aspiration, chronic post nasal drip, globus, sore throat, throat clearing);~* Presents with Reflux Symptom Index (RSI) \> 13;~* Undergoing Esophagogastroduodenoscopy (EGD) as part of routine care;~* Undergoing 96-hour pH monitoring via BRAVO capsule as part of routine care.~Exclusion Criteria:~* Currently being treated with another investigational medical device and/or drug;~* Currently receiving treatment for sleep apnea with continuous positive airway pressure (CPAP);~* Female patients who are of child-bearing potential and not using an acceptable method of birth control, or is pregnant or breast-feeding;~* Suspected esophageal cancer;~* Confirmed nasopharyngeal cancer;~* Previously undergone Nissen Fundoplication;~* Hiatal hernia \> 4 cm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Patients with nocturnal extraesophageal reflux (Type: EXPERIMENTAL): This is a non-randomized study to evaluate the effectiveness of the MedclineTM Sleep Assist Device on patients who experience nocturnal extraesophageal reflux. All patients will receive the device. Participants will serve as their own controls while undergoing 96-hour pH monitoring. Participants will follow their regular sleep position patterns on Days 1 and 2 of the study and will use the sleep assist device on Days 3 and 4. pH data and patient report of symptoms will be evaluated during the initial 96 hours of the study to capture physiologic results. All participants will use the sleep assist device for the remainder of the study to determine if a reduction in overall reflux symptom index (RSI) is achieved.

Based on this trial design, predict the completion outcome and termination type (if applicable).